Recent insider trends for Genocea Biosciences, Inc. (NASDAQ:GNCA) have caught the attention of investors. Analysts monitor insider data to understand the sentiment of a company’s largest and most important shareholders. GNCA’s insider trading patterns have some implications for where the stock might be headed.
Institutions own 12.04% of Genocea Biosciences, Inc. (GNCA)’s shares. The total value of these holdings, in millions, is $9. Among active positions in the latest quarter, 32 holders increased their positions by a total of 825497 shares, 23 holders decreased the positions by a total of 7.33 million shares, and 16 holders held their positions. This works out to a net decrease in ownership of 6.5 million shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 13 holders initiated new positions by a total of 603482 shares and 11 holders exited their positions by a total of 3.87 million shares. This nets out to a decrease of 3.26 million shares and is another bearish sign for GNCA.
In the last three months, insiders executed a total of 1 trades. 1 of these were buys. Insider ownership increased by a total of 25000 shares, which suggests that GNCA’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 4 buys and 3 sells, and ownership increased by a net of 55366 shares.
Comparing the number of shares sold short over time is a method analysts often use to get a reading on investor sentiment. Genocea Biosciences, Inc. (NASDAQ:GNCA)’s short interest is 1.65 million shares, or 7.28% of the float. This represents an increase of 11% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
Supplementing insider data with technical indicators can help an investor form a more complete view on the outlook for a stock. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that GNCA is a Weak sell, which implies that GNCA is expected to underperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Genocea Biosciences, Inc. (NASDAQ:GNCA) is overvalued.